Eplerenone
- Generic Name
- Eplerenone
- Brand Names
- Inspra
- Drug Type
- Small Molecule
- Chemical Formula
- C24H30O6
- CAS Number
- 107724-20-9
- Unique Ingredient Identifier
- 6995V82D0B
- Background
Eplerenone, an aldosterone receptor antagonist similar to spironolactone, has been shown to produce sustained increases in plasma renin and serum aldosterone, consistent with inhibition of the negative regulatory feedback of aldosterone on renin secretion. The resulting increased plasma renin activity and aldosterone circulating levels do not overcome the ef...
- Indication
For improvement of survival of stable patients with left ventricular systolic dysfunction (ejection fraction <40%) and clinical evidence of congestive heart failure after an acute myocardial infarction.
- Associated Conditions
- Hypertension, LVEF <40% Congestive heart failure, Chronic heart failure with reduced ejection fraction (NYHA Class II)
- Associated Therapies
- -
Eplerenone in Patients Undergoing REnal Transplant (EPURE TRANSPLANT)
- Conditions
- Interventions
- First Posted Date
- 2015-07-07
- Last Posted Date
- 2023-06-18
- Lead Sponsor
- Central Hospital, Nancy, France
- Target Recruit Count
- 132
- Registration Number
- NCT02490904
- Locations
- 🇫🇷
CHU Dijon- Hôpital Bocage Central, Dijon, France
🇫🇷CHRU Besançon, Besancon, France
🇫🇷CHU Brest, Brest, France
Therapeutic Potential for Aldosterone Inhibition in Duchenne Muscular Dystrophy
- Conditions
- Interventions
- First Posted Date
- 2015-02-03
- Last Posted Date
- 2019-10-07
- Lead Sponsor
- Ohio State University
- Target Recruit Count
- 52
- Registration Number
- NCT02354352
- Locations
- 🇺🇸
University of Colorado, Aurora, Colorado, United States
🇺🇸The Ohio State University Medical Center, Columbus, Ohio, United States
🇺🇸Mattel Children's Hospital and David Geffen School of Medicine at UCLA, Los Angeles, California, United States
A Study to Evaluate Efficacy and Safety of CS-3150 in Japanese Hypertensive Subjects
- Conditions
- Interventions
- First Posted Date
- 2015-01-26
- Last Posted Date
- 2019-10-08
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 426
- Registration Number
- NCT02345044
Eplerenone in the Management of Abdominal Aortic Aneurysms
- First Posted Date
- 2015-01-26
- Last Posted Date
- 2016-01-15
- Lead Sponsor
- Bayside Health
- Target Recruit Count
- 172
- Registration Number
- NCT02345590
- Locations
- 🇦🇺
Baker IDI, Melbourne, Victoria, Australia
🇦🇺Heart Centre, Alfred Health, Melbourne, Victoria, Australia
A Study of the Beneficial Effects of Eplerenone on Central Serous Chorioretinopathy
- First Posted Date
- 2014-08-13
- Last Posted Date
- 2014-08-13
- Lead Sponsor
- Prim. Prof. Dr. Oliver Findl, MBA
- Target Recruit Count
- 60
- Registration Number
- NCT02215330
- Locations
- 🇦🇹
Oliver Findl, Vienna, Austria
Eplerenone For the Treatment of Chronic Central Serous Chorioretinopathy
- First Posted Date
- 2014-06-02
- Last Posted Date
- 2014-06-02
- Lead Sponsor
- Tel-Aviv Sourasky Medical Center
- Target Recruit Count
- 30
- Registration Number
- NCT02153125
- Locations
- 🇮🇱
Tel Aviv Souraski Medical Center, Tel Aviv, Israel
The Effect of EPLerenone on Ischemia Reperfusion Injury in Human myoCARDium
- First Posted Date
- 2014-04-21
- Last Posted Date
- 2016-01-12
- Lead Sponsor
- Radboud University Medical Center
- Target Recruit Count
- 24
- Registration Number
- NCT02118753
- Locations
- 🇳🇱
Radboud University Medical Centre, Nijmegen, Gelderland, Netherlands
The Role of Aldosterone on Augmented Exercise Pressor Reflex in Hypertension
- First Posted Date
- 2013-11-27
- Last Posted Date
- 2022-03-18
- Lead Sponsor
- University of Texas Southwestern Medical Center
- Target Recruit Count
- 14
- Registration Number
- NCT01996449
- Locations
- 🇺🇸
UT Southwestern Medical Center, Dallas, Texas, United States
The Effects of Eplerenone on Markers of Myocardial Fibrosis in Adult Congenital Heart Disease
- Conditions
- Interventions
- First Posted Date
- 2013-10-29
- Last Posted Date
- 2018-05-04
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 26
- Registration Number
- NCT01971593
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
Phase IIb Safety and Efficacy Study of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Moderate Chronic Kidney Disease Alone
- First Posted Date
- 2013-10-07
- Last Posted Date
- 2021-07-16
- Lead Sponsor
- Bayer
- Target Recruit Count
- 72
- Registration Number
- NCT01955694
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.